Biote

Biote Change in Working Capital

The Change in Working Capital of Biote (BTMD) as of Oct 31, 2026 is -8.25 M USD. In the previous year, Change in Working Capital was 9.93 M USD — a change of -183.07% (lower).

Change in Working Capital

-8.25 MUSD

YoY

-183.07%

Last updated:

Change in Working Capital of Biote is 2025 -8.25 M USD. Change in Working Capital of Biote was 2024 9.93 M USD. It decreases by -183.07% lower compared to the previous year.

The Biote Change in Working Capital history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Change in Working Capital
Date
Change in Working Capital
Jan 1, 2019
2.40 M USD
Jan 1, 2020
-5.59 M USD
Jan 1, 2021
-1.46 M USD
Jan 1, 2022
-35.81 M USD
Jan 1, 2023
-8.93 M USD
Jan 1, 2024
9.93 M USD
Jan 1, 2025
-8.25 M USD
The Biote Change in Working Capital history
YEARChange in Working CapitalYoY
-8.25 MUSD-183.07%
9.93 MUSD-211.28%
-8.93 MUSD-75.07%
-35.81 MUSD+2,356.38%
-1.46 MUSD-73.91%
-5.59 MUSD-333.03%
2.40 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biote Stock analysis

What does Biote do? biote Corp. generates revenue through its Biote Method platform, which offers certified practitioners comprehensive tools for hormone optimization. The platform includes education, training, certification, practice management software, inventory management software, and marketing support. Biote also sells a branded line of dietary supplements directly to practitioners and patients. The company's primary customers are Biote-certified practitioners who use the platform to build and manage hormone optimization programs, while the dietary supplements target patients seeking complementary wellness solutions. The Biote Method's proprietary clinical decision support (CDS) system helps physicians personalize patient dosing, enhancing the value proposition for practitioners. By providing end-to-end solutions—from certification to software tools—biote Corp. creates recurring revenue streams through ongoing platform usage and product sales. The company's focus on hormone replacement therapy (HRT) products and practitioner support positions it within the specialized healthcare market segment for bio-identical hormone therapy. biote Corp. differentiates itself through its woman-led structure and comprehensive approach to hormone optimization. The firm's revenue model relies on both service-based offerings for practitioners and direct sales of branded supplements. This dual approach ensures consistent income from certified practitioners who depend on the platform for practice management and from patients purchasing the supplement line as part of their wellness regimen. Biote is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biote stock

Change in Working Capital of Biote is -8.25 M USD in 2025.

Change in Working Capital of Biote changed from 9.93 M USD to -8.25 M USD, representing a -183.07% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Change in Working Capital Biote since 2006 – with annual values, charts, and detailed analysis.

Change in working capital reflects the period-over-period change in current assets minus current liabilities. It impacts operating cash flow significantly.

Change in Working Capital's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Change in Working Capital's Biote historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Biote

All Key Metrics — Biote